A Phase II Study of ENMD-2076 in Patients with Fibrolamellar Liver Cancer

Full Title

A Phase 2 Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma (FLC)

Purpose

Fibrolamellar liver cancer is a rare form of liver cancer that is challenging to treat successfully. It is sometimes removed by surgery. There is no standard chemotherapy or other systemic therapy regimen that has been found to be effective for treating patients with inoperable fibrolamellar liver cancer.

In this study, researchers are evaluating the safety and effectiveness of an investigational drug called ENMD-2076 in patients with advanced fibrolamellar liver cancer that cannot be surgically removed. ENMD-2076 blocks a protein called protein kinase A, which may be important for the growth of fibrolamellar liver cancers. It also blocks other targets, including those that support the flow of blood to the cancer. It is taken orally (by mouth).

Eligibility

Almost all patients with fibrolamellar liver cancer are eligible for this study. Please contact us to learn more.

For more information and to inquire about eligibility for this study, please contact Dr. Ghassan Abou-Alfa at 646-888-4184.

Protocol

15-175

Phase

II

Investigator

Co-Investigators

Locations